基础医学与临床 ›› 2026, Vol. 46 ›› Issue (7): 887-894.doi: 10.16352/j.issn.1001-6325.2026.07.0887

• 研究论文 • 上一篇    下一篇

FBXO2是Vδ1 γδ T细胞识别的肿瘤相关异位蛋白质配体

刘睿琦, 张建民, 何维, 陈慧*   

  1. 中国医学科学院北京协和医学院 基础医学研究所 重大疾病共性机制研究全国重点实验室,北京 100005
  • 收稿日期:2026-03-30 修回日期:2026-06-21 发布日期:2026-06-23
  • 通讯作者: *chenhui_1980@126.com
  • 基金资助:
    国家自然科学基金(32270915); 中国医学科学院创新工程科技攻关项目(2025-I2M-KJ-012);常州西太湖细胞治疗前沿技术发展基金(2024-P-013)

FBXO2 is a potential tumor pattern recognition ligand of Vδ1 γδ T cells

LIU Ruiqi, ZHANG Jianmin, HE Wei, CHEN Hui*   

  1. State Key Laboratory of Common Mechanism Research of Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
  • Received:2026-03-30 Revised:2026-06-21 Published:2026-06-23
  • Contact: *chenhui_1980@126.com

摘要: 目的 验证F-Box蛋白2(FBXO2)是γδ T细胞识别的肿瘤相关应激异位蛋白质配体,为阐明γδ T细胞的抗原识别机制及在肿瘤免疫治疗中的应用奠定基础。方法 用Western blot和流式细胞测量术检测FBXO2在多种人实体瘤和血液瘤细胞系中的表达情况;固相化包被重组FBXO2蛋白,从人外周血单个核细胞(PBMC)中分别扩增Vδ2和Vδ1 γδ T细胞,检测细胞纯度、总细胞数、活化相关分子的表达及细胞因子的分泌水平;用特异性抗体杀伤封闭实验FBXO2抗体对Vδ2和Vδ1 γδ T细胞体外细胞毒活性的封闭效果。结果 FBXO2在多种人实体瘤和血液瘤细胞系中表达,其中在胃癌细胞系SNU601、淋巴细胞白血病细胞系Jurkat表面异位表达较高;固相包被FBXO2蛋白能显著促进Vδ1 γδ T细胞的扩增,但不能刺激Vδ2 γδ T扩增;Vδ1 γδ T细胞通过识别FBXO2蛋白发挥细胞毒活性,FBXO2抗体能在体外封闭其对SNU601和Jurkat细胞的毒作用,具有剂量依赖性。结论 异位表达于多种肿瘤细胞表面的FBXO2蛋白能够在体外促进Vδ1 γδ T细胞的扩增,并介导其对肿瘤细胞的细胞毒活性,是Vδ1 γδ T细胞识别的肿瘤相关异位蛋白质配体,有望成为肿瘤免疫治疗的新靶点。

关键词: Vδ1 γδ T细胞, F-Box蛋白2(FBXO2), 异位蛋白质, 肿瘤免疫治疗靶点

Abstract: Objective To validate F-box protein 2 (FBXO2) as a potential tumor-specific pattern recognition ligand for γδ T cells and to characterize its expression in tumor cells and function in immunotherapy. Methods The expression of FBXO2 in various human solid tumor and hematological tumor cell lines was detected by Western blot and flow cytometry. Immobilized FBXO2 recombinant protein was used to expand Vδ2 and Vδ1 γδ T cells from human peripheral blood mono-nuclear cell(PBMC), followed by comprehensive characterization of cellular purity, absolute counts, activation marker expression and cytokine secretion profiles. The inhibitory effect of FBXO2-specific antibody on the in vitro cytotoxicity of Vδ1and Vδ2 γδ T cells was evaluated via antibody blockade experiment. Results FBXO2 was expressed in some human solid and hematological tumor cell lines especially in the gastric cancer line SNU601 and the lymphocyte leukemia line Jurkat. Immobilized FBXO2 significantly promoted the expansion of Vδ1 γδ T cells but failed to stimulate Vδ2 γδ T cells. Vδ1 γδ T cells exerted cytotoxic activity by recognizing FBXO2 protein while FBXO2 antibody blocked their cytotoxic effects on SNU601 and Jurkat cells with a dose-dependent manner in vitro. Conclusions F-Box2 protein, ectopically expressed on a variety of tumor cell surface, may promote the expansion of Vδ1 γδ T cells and enhance the cytotoxicity of γδ T cells against tumor cells in vitro,so this protein molecule is believed to be a tumor-associated protein ligand recognized by γδ T cells. This result suggests a potential nascent target for cancer immunotherapy.

Key words: Vδ1 γδ T cell, F-box only protein 2(FBXO2), ectopic protein, tumor immunotherapy target

中图分类号: